NASDAQ · ESLA
Healthcare · Biotechnology
$0.66
Down-$0.01 (-1.99%)
Updated Sep 12, 2026, 5:05 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ESLA closed at $0.66 after 20 trading sessions, down 8.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.696 | $0.72 | $0.6596 | $0.6596 | 25.93K |
| Sep 10, 2026 | $0.62 | $0.74 | $0.62 | $0.673 | 82.73K |
| Sep 9, 2026 | $0.6101 | $0.6851 | $0.6101 | $0.638 | 28.58K |
| Sep 8, 2026 | $0.6222 | $0.72 | $0.62 | $0.6403 | 53.27K |
| Sep 4, 2026 | $0.725 | $0.7375 | $0.585 | $0.6463 | 69.52K |
| Sep 3, 2026 | $0.719 | $0.7439 | $0.64 | $0.641 | 17.29K |
| Sep 2, 2026 | $0.7031 | $0.725 | $0.69 | $0.69 | 17.45K |
| Sep 1, 2026 | $0.7201 | $0.725 | $0.6915 | $0.6915 | 4.88K |
| Aug 31, 2026 | $0.68 | $0.7295 | $0.6602 | $0.725 | 13.12K |
| Aug 28, 2026 | $0.755 | $0.755 | $0.6251 | $0.7051 | 44.29K |
| Aug 27, 2026 | $0.7402 | $0.75 | $0.7072 | $0.7219 | 41.82K |
| Aug 26, 2026 | $0.7502 | $0.7502 | $0.7247 | $0.73 | 11.86K |
| Aug 25, 2026 | $0.759 | $0.77 | $0.72 | $0.7325 | 38.29K |
| Aug 24, 2026 | $0.757 | $0.7635 | $0.72 | $0.735 | 20.29K |
| Aug 21, 2026 | $0.7605 | $0.7605 | $0.7206 | $0.7353 | 8.19K |
| Aug 20, 2026 | $0.77 | $0.77 | $0.72 | $0.745 | 29.71K |
| Aug 19, 2026 | $0.72 | $0.8013 | $0.72 | $0.7368 | 53.43K |
| Aug 18, 2026 | $0.77 | $0.8135 | $0.7312 | $0.7322 | 30.01K |
| Aug 17, 2026 | $0.735 | $0.85 | $0.7201 | $0.7602 | 96.84K |
| Aug 14, 2026 | $0.7352 | $0.74 | $0.7201 | $0.7232 | 9.06K |
The latest Smart Investors Daily articles mentioning ESLA.
ESLA research
Company profile and research snapshot.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 9, 2026 | D. Boral Capital | Buy | — |
| Jan 28, 2026 | D. Boral Capital | Buy | — |
| Nov 3, 2025 | D. Boral Capital | Buy | — |
| Aug 12, 2025 | D. Boral Capital | Buy | — |
| Jun 3, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 3, 2026
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and
Benzinga · Jul 29, 2026
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and
Benzinga · Jul 24, 2026
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and
Yahoo · Feb 9, 2026
By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell Non-Hodgkin Lymphoma (NHL) were presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ESLA.
